✦ LIBER ✦

Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus

✍ Scribed by Anne Bruns; Stefan Bläss; Gert Hausdorf; Gerd R. Burmester; Falk Hiepe

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 269 KB
Volume: 43
Category: Article
ISSN: 0004-3591
DOI: 10.1002/1529-0131(200010)43:10<2307::aid-anr19>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SR proteins are autoantigens in patients

SR proteins are autoantigens in patients with systemic lupus erythematosus: Importance of phosphoepitopes

✍ Karla M. Neugebauer; Joan T. Merrill; Mark H. Wener; Robert G. Lahita; Mark B. R 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 375 KB 👁 1 views

Abnormal T cell signal transduction in s

Abnormal T cell signal transduction in systemic lupus erythematosus

✍ Gary M. Kammer; Andras Perl; Bruce C. Richardson; George C. Tsokos 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 2 views

B cell biomarkers of rituximab responses

B cell biomarkers of rituximab responses in systemic lupus erythematosus

✍ Edward M. Vital; Shouvik Dass; Maya H. Buch; Karen Henshaw; Colin T. Pease; Mich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB 👁 2 views

Antibodies to human T cell leukemia viru

Antibodies to human T cell leukemia virus are absent in patients with systemic lupus erythematosus

✍ Takao Koike; Katsuhiko Takabayashi; Naoki Maruyama; Hisao Tomioka; Sho Yoshida 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

A B cell apotope of Ro 60 in systemic lu

A B cell apotope of Ro 60 in systemic lupus erythematosus

✍ Joanne H. Reed; Michael W. Jackson; Tom P. Gordon 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Rituximab improves peripheral B cell abn

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

✍ Jennifer H. Anolik; Jennifer Barnard; Amedeo Cappione; Aimee E. Pugh-Bernard; Ra 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB 👁 2 views

## Abstract ## Objective B lymphocyte depletion has recently emerged as a promising approach to the treatment of systemic lupus erythematosus (SLE). As part of a phase I/II dose‐ranging trial of rituximab in the treatment of SLE, we evaluated the fate of discrete B cell subsets in the setting of s